TIDAL THERAPEUTICS
Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.
TIDAL THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Total Employee:
11+
Status:
Active
Similar Organizations
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Earth Vision Bio Solutions
Earth Vision Bio Solutions is a biotech company specializing in packaging products of environmentally impact plastics.
Impairment Measurement Marijuana and Driving
IMMAD is a company that specializes in the responsible use of marijuana. IMMAD technology is a tool for law enforcement use roadside.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Kairos Therapeutics
Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform.
Orsenix
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide.
Current Advisors List
Board_observer
2020-02-01
Current Employees Featured
Ulrik Nielsen Co-Founder, President and CEO @ Tidal Therapeutics
Co-Founder, President and CEO
2019-04-01
Founder
More informations about "Tidal Therapeutics"
Sanofi acquires Tidal Therapeutics, adding innovative mRNAbased ...
Apr 9, 2017 Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas PARIS AND …See details»
Tidal Therapeutics - Crunchbase Company Profile
Organization. Tidal Therapeutics . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. Tidal Therapeutics is a preclinical …See details»
Sanofi acquires biotech company Tidal Therapeutics for …
Mar 24, 2022 At present, Tidal Therapeutics is progressing pre-clinical programmes, including in vivo reprogramming of T cells or other immune cell …See details»
Tidal Therapeutics 2025 Company Profile: Valuation, Investors ...
AbbVie Ventures, MRL Ventures Fund, Mission BioCapital, Myeloma Investment Fund, and New Enterprise Associates have invested in Tidal Therapeutics. When was Tidal Therapeutics …See details»
Sanofi buys an mRNA startup in another bet on 'off-the-shelf' cell ...
Apr 9, 2021 Sanofi on Friday agreed to acquire Tidal Therapeutics, a small, privately held, Cambridge, Massachusetts-based biotech developing messenger RNA-based treatments for …See details»
Sanofi Acquires Tidal Therapeutics and its Novel mRNA …
Apr 13, 2021 Sanofi announced the acquisition of Tidal Therapeutics, a privately held, pre-clinical stage biotech company with a revolutionary mRNA-based platform for in vivo immune cells reprogramming. Sanofi is focused on …See details»
Sanofi Snatches Up Tidal Therapeutics in $470 Million Deal
Apr 9, 2021 Keitma / Shutterstock. Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million. Under the terms of the agreement, Sanofi is …See details»
Sanofi Acquires Tidal Therapeutics and Adds an mRNA …
Apr 14, 2021 Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. “We anticipate that this next generation, off-the-shelf approach has the potential to …See details»
Tidal therapeutics - Company info. interviews, news
Apr 9, 2019 Tidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body …See details»
Tidal Therapeutics - LinkedIn
Tidal Therapeutics | 1,718 followers on LinkedIn. Reprogramming the Immune System | Developing next generation mRNA immunotherapiesSee details»
Tidal Therapeutics: the benefits and leverage of the ... - LabCentral
Jun 3, 2021 What does Tidal do? Like all biotech start-ups, Tidal Therapeutics was started with an ambitious idea: reprogramming the human immune system and developing next-generation …See details»
Tidal Therapeutics (Tidal Therapeutics) - 药物管线_专利_临床试验_ …
Astellas is not the only biopharma company pursuing in vivo cell therapies. In 2021, Sanofi acquired Tidal Therapeutics, a preclinical startup with technology that uses messenger RNA to …See details»
Tidal Therapeutics - Crunchbase Company Profile & Funding
Tidal Therapeutics is a preclinical biotech company with a novel mRNA-based approach for reprogramming immune cells. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Sanofi pays $160M for mRNA tech to reprogram T cells in vivo
Apr 12, 2021 The biotech, LabCentral-based Tidal Therapeutics, has kept a low public profile since spinning out of the Fred Hutchinson Cancer Research Center but still quickly attracted …See details»
Sanofi acquires Tidal Therapeutics, adding innovative
Apr 9, 2021 PARIS AND CAMBRIDGE, MA – April 9, 2021 – Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based …See details»
Sanofi to Go After mRNA Based Cancer Treatments, Acquires …
Apr 12, 2021 On April 9th, Sanofi announced buying Tidal therapeutics, a preclinical biotech company developing messenger RNA-based treatments for cancer. The French biopharma …See details»
Sanofi spends $160M in bet that Tidal’s tech gets it to off-the …
Apr 11, 2021 Tidal is based at LabCentral, a shared laboratory space for life science startups. Founded in 2019, it is led by Ulrik Nielsen, a former executive at Merrimack Pharmaceuticals …See details»
Sanofi acquires Tidal Therapeutics - Chemical & Engineering News
Apr 17, 2021 Sanofi has acquired the messenger RNA (mRNA) therapy start-up Tidal Therapeutics for $160 million up front and up to $310 million in milestone payments. Tidal, …See details»
Sanofi to Acquire Tidal Therapeutics for $470 Million - PharmTech
Sanofi announced on April 9, 2021 that it has acquired Tidal Therapeutics, a US-based pre-clinical stage biotech company, for $470 million. Under the terms of the agreement, Sanofi will …See details»
Sanofi buys mRNA-focused Tidal Therapeutics in $470M deal
Apr 12, 2021 In a move that Sanofi SA said will bring it an mRNA-based research platform with applications in oncology, immunology and other diseases, the company has acquired Tidal …See details»